APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin Converting Enzyme (ACE) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast 2026-2032

Report ID 173963670221 December 2025193 pages

Choose your research edition.

Industry ResearchAngiotensin Converting Enzyme (ACE) Inhibitors Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Angiotensin Converting Enzyme (ACE) Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Angiotensin Converting Enzyme (ACE) Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Angiotensin Converting Enzyme (ACE) Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Angiotensin Converting Enzyme (ACE) Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Angiotensin Converting Enzyme (ACE) Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Angiotensin Converting Enzyme (ACE) Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Angiotensin Converting Enzyme (ACE) Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

Abbott Laboratories

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type

Dicarboxylate-containing Agents

Sulfhydryl-containing Agents

Phosphonate-containing Agents

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Converting Enzyme (ACE) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Converting Enzyme (ACE) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Converting Enzyme (ACE) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Angiotensin Converting Enzyme (ACE) Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Angiotensin Converting Enzyme (ACE) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Angiotensin Converting Enzyme (ACE) Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Dicarboxylate-containing Agents Major Manufacturers Table 3. Sulfhydryl-containing Agents Major Manufacturers Table 4. Phosphonate-containing Agents Major Manufacturers Table 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cardiovascular Diseases Major Manufacturers Table 7. Kidney Diseases Major Manufacturers Table 8. Hypertension Major Manufacturers Table 9. Other Major Manufacturers Table 10. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends Table 11. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers Table 12. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges Table 13. Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints Table 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2026) Table 18. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2027-2032) Table 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k tons) Table 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2026) & (k tons) Table 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2027-2032) & (k tons) Table 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2021-2026) Table 23. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2027-2032) Table 24. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price (US$/ton) of Manufacturers (2021-2026) Table 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers, Product Type & Application Table 32. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Angiotensin Converting Enzyme (ACE) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2026) Table 39. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2027-2032) Table 40. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 41. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 42. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 43. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2026) Table 44. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2027-2032) Table 45. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2026) & (US$/ton) Table 46. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2027-2032) & (US$/ton) Table 47. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2026) Table 51. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2027-2032) Table 52. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 53. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 54. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 55. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2026) Table 56. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2027-2032) Table 57. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2026) & (US$/ton) Table 58. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2027-2032) & (US$/ton) Table 59. Teva Pharmaceutical Company Information Table 60. Teva Pharmaceutical Business Overview Table 61. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 62. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 63. Teva Pharmaceutical Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 68. Sanofi Recent Development Table 69. Jhonson and Johnson Company Information Table 70. Jhonson and Johnson Business Overview Table 71. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 73. Jhonson and Johnson Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 78. Novartis Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 83. Merck Recent Development Table 84. Eli Lilly Company Information Table 85. Eli Lilly Business Overview Table 86. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 88. Eli Lilly Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 93. Pfizer Recent Development Table 94. GSK Company Information Table 95. GSK Business Overview Table 96. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 98. GSK Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 103. Bayer Recent Development Table 104. Bristol-Myers Squibb Company Information Table 105. Bristol-Myers Squibb Business Overview Table 106. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 108. Bristol-Myers Squibb Recent Development Table 109. Astra Zeneca Company Information Table 110. Astra Zeneca Business Overview Table 111. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 113. Astra Zeneca Recent Development Table 114. Abbott Laboratories Company Information Table 115. Abbott Laboratories Business Overview Table 116. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio Table 118. Abbott Laboratories Recent Development Table 119. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 122. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 123. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2021-2026) & (US$/ton) Table 124. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2027-2032) & (US$/ton) Table 125. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 128. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 129. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2021-2026) & (US$/ton) Table 130. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2027-2032) & (US$/ton) Table 131. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 135. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 136. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 137. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2021-2026) & (US$/ton) Table 138. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2027-2032) & (US$/ton) Table 139. United States Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 140. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 141. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 142. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 145. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 146. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2021-2026) & (US$/ton) Table 147. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2027-2032) & (US$/ton) Table 148. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 149. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 150. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 151. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 152. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2021-2026) & (US$/ton) Table 153. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2027-2032) & (US$/ton) Table 154. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 156. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 157. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 158. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 159. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 160. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2021-2026) & (US$/ton) Table 161. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2027-2032) & (US$/ton) Table 162. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 163. France Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 164. U.K. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 165. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 166. Russia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 167. Spain Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 168. Netherlands Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 169. Switzerland Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 170. Sweden Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 171. Poland Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 172. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 173. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 174. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 175. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 176. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2021-2026) & (US$/ton) Table 177. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2027-2032) & (US$/ton) Table 178. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 179. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 180. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 181. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 182. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2021-2026) & (US$/ton) Table 183. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2027-2032) & (US$/ton) Table 184. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 187. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 188. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2021-2026) & (US$/ton) Table 189. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2027-2032) & (US$/ton) Table 190. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 193. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 194. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2021-2026) & (US$/ton) Table 195. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2027-2032) & (US$/ton) Table 196. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 200. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 201. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 202. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2021-2026) & (US$/ton) Table 203. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2027-2032) & (US$/ton) Table 204. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 205. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 206. India Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 207. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 208. Taiwan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 209. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 210. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 211. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 212. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2026) & (k tons) Table 213. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2027-2032) & (k tons) Table 214. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2021-2026) & (US$/ton) Table 215. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Type (2027-2032) & (US$/ton) Table 216. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 217. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 218. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2026) & (k tons) Table 219. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2027-2032) & (k tons) Table 220. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2021-2026) & (US$/ton) Table 221. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Application (2027-2032) & (US$/ton) Table 222. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 226. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021-2026) & (k tons) Table 227. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2027-2032) & (k tons) Table 228. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2021-2026) & (US$/ton) Table 229. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Country (2027-2032) & (US$/ton) Table 230. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 231. Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 232. Chile Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 233. Colombia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 234. Peru Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 235. Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 236. Israel Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 237. UAE Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 238. Turkey Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 239. Iran Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 240. Egypt Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List Table 244. Angiotensin Converting Enzyme (ACE) Inhibitors Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Angiotensin Converting Enzyme (ACE) Inhibitors Image Figure 2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Dicarboxylate-containing Agents Image Figure 5. Sulfhydryl-containing Agents Image Figure 6. Phosphonate-containing Agents Image Figure 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cardiovascular Diseases Image Figure 10. Kidney Diseases Image Figure 11. Hypertension Image Figure 12. Other Image Figure 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2032) Figure 18. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (2021-2032) & (k tons) Figure 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY (2021-2032) & (k tons) Figure 22. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY (2021-2032) & (k tons) Figure 23. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY (2021-2032) & (k tons) Figure 24. Asia (Excluding China) Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY (2021-2032) & (k tons) Figure 25. South America, Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales YoY (2021-2032) & (k tons) Figure 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032) Figure 32. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 33. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032) Figure 35. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032) Figure 38. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 39. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032) Figure 41. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2021-2032) Figure 42. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Type (2021-2032) Figure 43. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2021-2032) Figure 44. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Application (2021-2032) Figure 45. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country (2021-2032) Figure 46. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Country (2021-2032) Figure 47. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2021-2032) Figure 48. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Type (2021-2032) Figure 49. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2021-2032) Figure 50. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Application (2021-2032) Figure 51. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country (2021-2032) Figure 52. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Country (2021-2032) Figure 53. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2021-2032) Figure 54. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Type (2021-2032) Figure 55. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2021-2032) Figure 56. China Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Application (2021-2032) Figure 57. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2021-2032) Figure 58. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Type (2021-2032) Figure 59. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2021-2032) Figure 60. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Application (2021-2032) Figure 61. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country (2021-2032) Figure 62. Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Country (2021-2032) Figure 63. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2021-2032) Figure 64. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Type (2021-2032) Figure 65. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2021-2032) Figure 66. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Application (2021-2032) Figure 67. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Country (2021-2032) Figure 68. SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Country (2021-2032) Figure 69. Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles

Scope & coverage.

Types
  • Dicarboxylate-containing Agents
  • Sulfhydryl-containing Agents
  • Phosphonate-containing Agents
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Type
  3. 1.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Dicarboxylate-containing Agents
  5. 1.2.3 Sulfhydryl-containing Agents
  6. 1.2.4 Phosphonate-containing Agents
  7. 1.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Application
  8. 1.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cardiovascular Diseases
  10. 1.3.3 Kidney Diseases
  11. 1.3.4 Hypertension
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics
  1. 2.1 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends
  2. 2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Drivers
  3. 2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region
  3. 3.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region
  9. 3.4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Angiotensin Converting Enzyme (ACE) Inhibitors Tier 1, Tier 2, and Tier 3
5 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Type
  1. 5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type
  2. 5.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
  6. 5.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032) & (k tons)
  8. 5.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type
6 Angiotensin Converting Enzyme (ACE) Inhibitors Market by Application
  1. 6.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application
  2. 6.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
  6. 6.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032) & (k tons)
  8. 6.2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceutical
  2. 7.1.1 Teva Pharmaceutical Company Information
  3. 7.1.2 Teva Pharmaceutical Business Overview
  4. 7.1.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Jhonson and Johnson
  14. 7.3.1 Jhonson and Johnson Company Information
  15. 7.3.2 Jhonson and Johnson Business Overview
  16. 7.3.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  18. 7.3.5 Jhonson and Johnson Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck
  26. 7.5.1 Merck Company Information
  27. 7.5.2 Merck Business Overview
  28. 7.5.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  30. 7.5.5 Merck Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Bristol-Myers Squibb
  56. 7.10.1 Bristol-Myers Squibb Company Information
  57. 7.10.2 Bristol-Myers Squibb Business Overview
  58. 7.10.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb Recent Developments
  61. 7.11 Astra Zeneca
  62. 7.11.1 Astra Zeneca Company Information
  63. 7.11.2 Astra Zeneca Business Overview
  64. 7.11.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  66. 7.11.5 Astra Zeneca Recent Developments
  67. 7.12 Abbott Laboratories
  68. 7.12.1 Abbott Laboratories Company Information
  69. 7.12.2 Abbott Laboratories Business Overview
  70. 7.12.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio
  72. 7.12.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type
  2. 8.1.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application
  6. 8.2.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country
  10. 8.3.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type
  2. 9.1.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application
  6. 9.2.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country
  10. 9.3.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type
  2. 10.1.1 China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
  5. 10.2 China Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application
  6. 10.2.1 China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type
  2. 11.1.1 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application
  6. 11.2.1 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country
  10. 11.3.1 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Angiotensin Converting Enzyme (ACE) Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Angiotensin Converting Enzyme (ACE) Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Angiotensin Converting Enzyme (ACE) Inhibitors Value Chain Analysis
  2. 13.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Angiotensin Converting Enzyme (ACE) Inhibitors Production Mode & Process
  6. 13.2 Angiotensin Converting Enzyme (ACE) Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors
  9. 13.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst